Tag: Jim Ballance
PhaseBio poised to make rapid strides in the Anti-Coagulant Reversal Market
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019....
We are looking for talented interns to learn and help investors find valuable companies.